Pacific Edge Limited

OTCPK:PFGT.F Stock Report

Market Cap: US$66.0m

Pacific Edge Valuation

Is PFGT.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PFGT.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PFGT.F's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PFGT.F's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PFGT.F?

Key metric: As PFGT.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for PFGT.F. This is calculated by dividing PFGT.F's market cap by their current revenue.
What is PFGT.F's PS Ratio?
PS Ratio4.6x
SalesNZ$21.92m
Market CapNZ$112.04m

Price to Sales Ratio vs Peers

How does PFGT.F's PS Ratio compare to its peers?

The above table shows the PS ratio for PFGT.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.5x
CTMX CytomX Therapeutics
0.6x-17.2%US$79.8m
HOWL Werewolf Therapeutics
25.9x61.3%US$87.8m
CELU Celularity
1xn/aUS$44.2m
AADI Aadi Bioscience
2.2x38.8%US$56.2m
PFGT.F Pacific Edge
4.6xn/aUS$112.0m

Price-To-Sales vs Peers: PFGT.F is good value based on its Price-To-Sales Ratio (4.6x) compared to the peer average (7.5x).

Price to Sales Ratio vs Industry

How does PFGT.F's PS Ratio compare vs other companies in the US Biotechs Industry?

124 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIIB Biogen
2.4x1.3%US$23.29b
MRNA Moderna
3.3x6.7%US$16.70b
INCY Incyte
3.6x9.0%US$14.54b
ALKS Alkermes
3.2x-0.7%US$4.74b
PFGT.F 4.6xIndustry Avg. 10.0xNo. of Companies124PS01632486480+
124 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: PFGT.F is good value based on its Price-To-Sales Ratio (4.6x) compared to the US Biotechs industry average (10x).

Price to Sales Ratio vs Fair Ratio

What is PFGT.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PFGT.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.6x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate PFGT.F's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PFGT.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$0.091
0%
3.2%US$0.094US$0.088n/a2
Nov ’25n/a
US$0.094
0%
9.7%US$0.10US$0.085n/a2
Oct ’25n/a
US$0.08
0%
7.7%US$0.086US$0.074n/a2
Sep ’25n/a
US$0.08
0%
7.7%US$0.086US$0.074n/a2
Aug ’25n/a
US$0.08
0%
7.7%US$0.086US$0.074n/a2
Jul ’25n/a
US$0.08
0%
7.7%US$0.086US$0.074n/a2
Jun ’25n/a
US$0.08
0%
7.7%US$0.086US$0.074n/a2
May ’25US$0.06
US$0.081
+34.5%
18.5%US$0.096US$0.066n/a2
Apr ’25US$0.064
US$0.088
+37.5%
10.3%US$0.097US$0.079n/a2
Mar ’25n/a
US$0.088
0%
10.3%US$0.097US$0.079n/a2
Feb ’25n/a
US$0.085
0%
14.3%US$0.097US$0.073n/a2
Jan ’25US$0.069
US$0.088
+27.4%
12.3%US$0.098US$0.077n/a2
Dec ’24US$0.058
US$0.088
+49.9%
12.3%US$0.098US$0.077n/a2
Nov ’24n/a
US$0.089
0%
8.5%US$0.096US$0.081n/a2
Aug ’24n/a
US$0.16
0%
56.6%US$0.29US$0.098n/a3
Jul ’24n/a
US$0.16
0%
56.6%US$0.29US$0.098n/a3
Jun ’24n/a
US$0.35
0%
22.0%US$0.45US$0.29n/a3
May ’24n/a
US$0.37
0%
20.3%US$0.47US$0.30US$0.063
Apr ’24n/a
US$0.37
0%
19.3%US$0.46US$0.30US$0.0643
Mar ’24n/a
US$0.38
0%
19.3%US$0.48US$0.31n/a3
Feb ’24n/a
US$0.38
0%
19.3%US$0.48US$0.31n/a3
Jan ’24US$0.28
US$0.38
+37.5%
19.1%US$0.48US$0.31US$0.0693
Dec ’23n/a
US$0.38
0%
19.1%US$0.47US$0.30US$0.0583
Nov ’23n/a
US$0.45
0%
8.4%US$0.49US$0.40n/a3

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Teva Pharmaceutical Industries

US$18.8b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$16.57

7D

-3.2%

1Y

70.6%

Collegium Pharmaceutical

US$990.4m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.71

7D

2.5%

1Y

20.0%

IQVIA Holdings

US$36.6b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$201.43

7D

-0.2%

1Y

-7.1%